Research Library / Blends / GLOW
Blends researchGLOW
BPC-157 + TB-500 + GHK-Cu blend
A community-named blend combining BPC-157, TB-500 and GHK-Cu. The listed community schedules describe individual components; they do not establish a single total-blend amount or frequency. An illustrative 70 mg total-blend vial at an assumed 2 mL final volume yields 35 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 70mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 35mg/mL · conditional arithmetic
- One U-100 marking
- 350mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryClinicalTrials.govReported schedule context
- Range
- Component-specific; fixed ratio varies
- Frequency
- Daily BPC-157 and GHK-Cu; intermittent TB-500
- Route
- Usually subcutaneous in community reports
- Reported half-life
- Varies by component
- Reported cycle
- 4–8 weeks commonly reported
The component schedules are displayed separately because no validated fixed-ratio GLOW protocol exists.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| BPC-157 component schedule | 250 mcg | 500 mcg/day | Twice daily | Morning and evening | Subcutaneous | Community-reported |
| TB-500 component schedule | 2–2.5 mg | 4–5 mg/week | Twice weekly | Evenly spaced | Subcutaneous | Community-reported |
| GHK-Cu component schedule | 1–2 mg | 1–2 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
20 example portions per vial
20 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
3.5 mg total blend · 35 mg/mL · 0.1 mL · 10 units
This calculation treats the vial as 70 mg total blend. At 35 mg/mL, 0.1 mL (10 U-100 units) contains 3.5 mg of the combined blend; each component amount depends on the vial's stated ingredient ratio. The 70 mg same-vial blend contains a copper complex together with other peptides. Evidence for separately prepared ingredients does not establish stability or compatibility of the finished mixture. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
70 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · BPC-157 component schedule
Vial counts and final solution totals below use the selected 70 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 250 mcg | Twice daily | 3.5 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 14 mg | 1 × 70 mg |
| 8 weeks | 28 mg | 1 × 70 mg |
| 12 weeks | 42 mg | 1 × 70 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2 mL | Not established |
| 8 weeks | 2 mL | Not established |
| 12 weeks | 2 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 56 |
| 8 weeks | 112 |
| 12 weeks | 168 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 280 administrations
8 weeks: 280 administrations
12 weeks: 280 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- GLOW · BPC-157 + TB-500 + GHK-Cu blend
- Evidence / status
- Unestablished blend. No FDA-approved combination product
- Clinical route, frequency & duration
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- Skin and tissue-repair discussions combining the community-reported purposes of BPC-157, TB-500, and GHK-Cu.
- Reported timing / route
- Daily BPC-157 and GHK-Cu; intermittent TB-500 · Usually subcutaneous in community reports. Schedule-specific timing remains in the Community tab.
- Reported half-life
- Varies by component · community-reference context, not a shelf life.
- Reported cycle
- 4–8 weeks commonly reported. Planning horizons do not establish a validated cycle.
Community-reported component loading phase
Initial phase: First 4–6 weeks
Pattern: TB-500 component: 2–2.5 mg twice weekly; other components remain on their separately reported schedules
Transition: Then the TB-500 component is commonly reduced to 2–2.5 mg once weekly
The loading phase applies to the TB-500 component, not automatically to the entire blend. Exact component ratios determine any valid volume calculation.
Reconstitution & formulation
The 70 mg same-vial blend contains a copper complex together with other peptides. Evidence for separately prepared ingredients does not establish stability or compatibility of the finished mixture.
Other vehicles and approaches discussed
Vendor water/PBS and chelator warnings are product-specific. Adding acid, PBS or another ingredient is not a validated way to rescue a cloudy blend.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Copper-containing finished-blend compatibility unresolved
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Copper-containing finished-blend compatibility unresolved
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Combines proposed cytoprotective, cell-migration and copper-binding tissue signaling
A community-named blend combining BPC-157, TB-500 and GHK-Cu. Evidence for the individual components does not establish the safety, efficacy or pharmacokinetics of the mixture.
Community-reported purpose
Skin and tissue-repair discussions combining the community-reported purposes of BPC-157, TB-500, and GHK-Cu.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Evidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
No controlled human trial has established a fixed ratio, combined protocol, interaction profile or long-term safety for this blend.
Development and regulatory status
No FDA-approved combination product
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is GLOW?
A community-named blend combining BPC-157, TB-500 and GHK-Cu. Evidence for the individual components does not establish the safety, efficacy or pharmacokinetics of the mixture.
Combines proposed cytoprotective, cell-migration and copper-binding tissue signaling
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
Community-reported component loading phase: First 4–6 weeks. The loading phase applies to the TB-500 component, not automatically to the entire blend. Exact component ratios determine any valid volume calculation.
4–8 weeks commonly reported
Which diluent and storage period should this material use?
The 70 mg same-vial blend contains a copper complex together with other peptides. Evidence for separately prepared ingredients does not establish stability or compatibility of the finished mixture.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeClinicalTrials.gov: Evidence landscape
- Research study — applies to its stated conditionsGHK-Cu dermal preformulation study
- Laboratory supplier or secondary reference — product-specificGLOW supplier handling page
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.